Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Abstract Text:

Darren R Feldman,G Varuni Kondagunta,Michelle S Ginsberg,Nicole Ishill,Sujata Patil,John Cestaro,Eugenie Obbens,Joel Sheinfeld,George J Bosl,Robert J Motzer,

In a phase I study, ixabepilone, a novel non-taxane microtubule-stabilizing agent, demonstrated activity against both paclitaxel-sensitive and paclitaxel-refractory solid tumors. We conducted a phase II trial of this agent in patients with advanced germ cell tumors (GCT) who were resistant to conventional therapies. Patients with cisplatin-refractory GCT were enrolled in this single-institution, phase II trial. Ixabepilone was administered at a dose of 40 mg/m2 intravenously over 3 hours every 21 days. Dose modifications were planned according to a nomogram for adverse events. Responses were assessed every 6 weeks using tumor markers and radiographic imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST). Patients who progressed (>or=20% increase in tumor size or rising serum tumor markers) were taken off protocol. Twenty-nine cycles of treatment were administered to 12 patients. The most common Grade 3/4 toxicities were leukopenia, lymphopenia, and neutropenia. One patient (8%) achieved a confirmed objective partial response but this patient had not received prior treatment with a taxane. Based on slow accrual and a lack of antitumor activity in patients previously treated with a taxane, the trial was closed after enrolling 12 patients. For patients who had previously received taxane therapy, ixabepilone was not efficacious in the treatment of cisplatin-refractory GCT.

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Publishing Authors By Initials

DR Feldman,GV Kondagunta,MS Ginsberg,N Ishill,S Patil,J Cestaro,E Obbens,J Sheinfeld,GJ Bosl,RJ Motzer,

For similar neoplasms: neoplasms by histologic type: neoplasms, germ cell and embryonal research abstracts see: neoplasms: neoplasms by histologic type: neoplasms, germ cell and embryonal research

PUBMED ID PMID:

MEDLINE DATE:

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Investigational new drugs

VOLUME: 25

Page Numbers: 487-90

Journal Abbreviation:

ISSN: 0167-6997

DAY: 23

MONTH: 05

YEAR: 2007

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309330

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Keywords Mesh Terms:

KEYWORDS: Neoplasms, Germ Cell and Embryonal

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Information

Substance Name: ixabepilone

Registry Number: 219989-84-1

Grant and Affiliation Information for Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.

AFFILIATION: Genitourinary service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

Country: United States

AGENCY: United States NCI

GRANT: CM-57732

ACRONYM: CM

MEDLINETA: Invest New Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors Related Publications

• A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
• Controlling unemployment compensation costs: good personnel administration.
• Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
• Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
• Medical treatment of advanced testicular cancer.
• Phase II Trial of Pegylated Interferon-alpha2b in Patients with Advanced Renal Cell Carcinoma.
• Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
• Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
• Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
• Stage I testicular cancer management and necessity for surgical expertise.
• Sunitinib therapy in renal cell carcinoma.
• Treatment options in renal cell carcinoma: past, present and future.